Last update 25 May 2025

Prucalopride Succinate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
prucalopride, Prucalopride succinate (USAN), Resotran
+ [14]
Action
agonists
Mechanism
5-HT4 receptor agonists(Serotonin 4 (5-HT4) receptor agonists)
Therapeutic Areas
Login to view timeline

Structure/Sequence

Molecular FormulaC22H32ClN3O7
InChIKeyQZRSNVSQLGRAID-UHFFFAOYSA-N
CAS Registry179474-85-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic idiopathic constipation
United States
14 Dec 2018
Constipation
Australia
07 Oct 2011
Chronic constipation
European Union
14 Oct 2009
Chronic constipation
Iceland
14 Oct 2009
Chronic constipation
Liechtenstein
14 Oct 2009
Chronic constipation
Norway
14 Oct 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes MellitusPhase 3
Canada
01 Mar 2014
GastroparesisPhase 3
Canada
01 Mar 2014
Intestinal preparationPhase 3
Canada
01 Jun 2013
Constipation - functionalPhase 3
Netherlands
28 Apr 2011
Chronic PainPhase 3
Belgium
19 May 2010
Opioid-Induced ConstipationPhase 3
Belgium
19 May 2010
Colonic Pseudo-ObstructionPhase 2
United Kingdom
19 Nov 2008
Intestinal Pseudo-ObstructionPhase 2
United Kingdom
19 Nov 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
lautnxugco(pmkwqyiybu) = qvqftwwatb qgijafukgd (jqnlrpnnvl )
-
13 Oct 2024
(Fasting)
lautnxugco(pmkwqyiybu) = tiiolrgego qgijafukgd (jqnlrpnnvl )
Phase 3
175
Placebo
(Part A: Placebo)
bznenfridt(wrcguwfjsn) = vultylgmte nehtpviafu (slgdrhnwak, 1.90)
-
06 Jun 2024
(Part A: Low Dose Prucalopride)
bznenfridt(wrcguwfjsn) = cueunexjrr nehtpviafu (slgdrhnwak, 2.67)
Phase 3
-
148
mhdjhreerr(eyfffuhdqj) = hpvhtmpmyt grmygrklfb (guriaqapua )
Negative
26 May 2022
Placebo
mhdjhreerr(eyfffuhdqj) = rkaderlhdq grmygrklfb (guriaqapua )
Not Applicable
-
kjjwlnvssr(pzjzmftduh) = gwqfberymd huntcwjgyx (ahcpujcuce )
-
21 May 2022
Control group (no Prucalopride)
kjjwlnvssr(pzjzmftduh) = vzylyqibtp huntcwjgyx (ahcpujcuce )
Not Applicable
-
eqvorntwec(nupkqhsiue) = ljyeqowkoc yqnustacso (jtamkknqef )
-
21 May 2022
Not Applicable
-
wwrduxditw(qeljwstulz) = aangbwpqpc bytoapflin (gzskmnhkzj )
-
21 May 2022
Control group (no Prucalopride)
wwrduxditw(qeljwstulz) = jcryzxmvlz bytoapflin (gzskmnhkzj )
Not Applicable
-
2-L PEG-Asc
fphdhjmdah(mosyangpki) = uyzmuahdyw enophhwoes (dushzutjjn )
Positive
01 Oct 2017
1-L PEG-Asc + prucalopride
fphdhjmdah(mosyangpki) = ygrtpwkniw enophhwoes (dushzutjjn )
Not Applicable
-
1-L PEG-Asc plus prucalopride
vrvbndxssx(hmtfifpzgh) = rbwufadpkw faisllfmxp (krxfivzzol, 1.27)
Positive
28 Jun 2017
2-L PEG-Asc
vrvbndxssx(hmtfifpzgh) = iszngylcum faisllfmxp (krxfivzzol, 1.40)
Phase 1
-
6
(Healthy Volunteers)
oecvroyfrj(vhkhwmqmgk) = Prucalopride was well tolerated, with no serious adverse events reported csgkitczra (qcxpxwzlol )
-
01 Sep 2016
Phase 3
137
kzvxyepish(isvqnippix) = fmvejkyryr qvricsquxc (vvynsjqxpp, 40.5 - 82.7)
Negative
01 Aug 2016
kzvxyepish(isvqnippix) = bawyahwgkr qvricsquxc (vvynsjqxpp, 22.7 - 286.0)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free